Gut microbiome for predicting immune checkpoint blockade-associated adverse events

Table 1 Clinical features of the studies employed in this investigation

Study	Tumor type	Treatment	Group		BMI(%)	Sex F(%)/M(%)
Chau et al. [31]^a	Lung cancer	anti-PD1	irAEs (n = 16); non-irAEs (n = 12)	-	-	-
Hakozaki et al. [32]^a,b	Lung cancer	anti-PD1/PD-L1	irAEs (n = 16); non-irAEs (n = 54)	69.71 ± 9.58	-	42.3/57.7
Zhang et al. [33]^a,b	Lung cancer	anti-PD1/PD-L1	irAEs (n = 26); non-irAEs (n = 43)	65.61 ± 9.56	< 25(47.1); ≥ 25(45.7); NE(7.1)	29.0/71.0
McCulloch et al. [20]^a,b	Melanoma	anti-PD-1	irAEs (n = 35); non-irAEs (n = 16)	67.36 ± 12.48	< 25(19.6); ≥ 25(80.4)	35.3/64.7
Chaput et al. [34]^a	Melanoma	anti-CTLA-4	irAEs (n = 7); non-irAEs (n = 19)	-	-	-
Dubin et al.^a	Melanoma	anti-CTLA-4	irAEs (n = 10); non-irAEs (n = 24)	-	-	-
Cascone et al.	Lung cancer	Combined	irAEs (n = 20); non-irAEs (n = 19)	-	-	-
SH Cohort (in-house)^c	Multi-type	anti-PD1/PD-L1	irAEs (n = 23); non-irAEs (n = 42)	63.57 ± 12.07	> 25 (15.4); ≤ 25(84.6)	26.2/73.8
JS Cohort (in-house)^c	Multi-type	anti-PD1/PD-L1	irAEs (n = 16); non-irAEs (n = 34)	61.94 ± 13.17	> 25(20); ≤ 25(78); NE(2)	22.0/78.0

Note: Each study is indicated by first author and year of publication. ^aStudies utilized for reanalyzing the differential microbes between irAEs and non-irAEs. ^bStudies utilized for constructing predictive microbial Random Forest classifier for anti-PD-1/PD-L1-associated irAEs. ^cStudies utilized as external validation. PD-1 programmed death 1, PD-L1 programmed death ligand 1, CTLA-4 cytotoxic T lymphocyte-associated antigen 4, NE/- not evaluated/not available

ISSN: 1756-994X